Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5603107 | Heart Rhythm | 2017 | 30 Pages |
Abstract
AAVCASQ2 displays a long-lasting capacity to attenuate and potentially cure CPVT2. Systemic delivery is feasible and convenient, reproducibly providing adequate levels of transgene expression. Antiarrhythmic efficacy depends on the CASQ2 level: â¥33% of the normal CASQ2 level is needed to prevent arrhythmia. However, even lower levels of protein protect from sustained VT, thereby potentially reducing the risk of sudden death.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Efrat PhD, Dor MSc, Shiraz MSc, Maayan MSc, Dan MD, Asher PhD, Michael MD, FHRS, Edith PhD, Michael MD,